Frequently Asked Questions About Biotech Consulting

We collaborate with a wide range of clients in the oncology space, including small and emerging biopharmaceutical companies, diagnostics firms, medical device developers, and academic research institutions. Our work spans early-stage startups from pre-clinical development thru end of P2 meetings, where we then work with your team to determine the best way forward for us to support you with large, global registrational studies. We tailor our services to support needs in drug development, due diligence efforts, and regulatory strategy specifically within the oncology domain.

We provide strategic and operational support across the entire oncology drug development lifecycle. This includes target identification and validation, clinical trial design and conduct, biomarker and vendor strategy, regulatory pathway planning, and competitive intelligence. Our deep understanding of tumor biology, evolving treatment paradigms, clinical trial conduct and regulatory requirements helps accelerate development and increase the likelihood of success.

Yes, our team has extensive experience with cutting-edge oncology modalities, including CAR-T therapies, TCR-based treatments, gene editing approaches, and checkpoint inhibitors. Our consultants stay abreast of the rapidly evolving scientific landscape and can guide clients on scientific positioning, clinical development strategy, and competitive differentiation for these complex therapies.

We assist with comprehensive commercialization planning, including market opportunity assessment, segmentation and targeting strategies, go-to-market models, pricing and reimbursement strategy, and stakeholder engagement planning. Our team combines scientific rigor with market insights to ensure successful product launches and sustained growth in competitive oncology markets.

Our consultants maintain active engagement with the oncology ecosystem through continuous literature review, participation in scientific and medical conferences (e.g., ASCO, ESMO, AACR), and collaborations with key opinion leaders. We also use market tracking tools and analytics to monitor industry trends, pipeline developments, and changes in treatment guidelines and regulator guidance.

We provide comprehensive due diligence support to help clients evaluate potential oncology assets or new indications with scientific, clinical, commercial, and regulatory rigor. Our approach includes a deep dive into the mechanism of action, preclinical and clinical data, competitive landscape, differentiation potential, biomarker strategy, and unmet medical need. We assess the asset's strategic fit, identify key risks and assumptions, and provide clear go/no-go recommendations. Whether for in-licensing, partnerships, or acquisitions, our insights enable clients to make informed decisions grounded in the complexities of oncology development and commercialization.  Our team has relationships with many of the major US academic medical centers who have products under discovery in their own labs, and who are actively looking for in-licensing opportunities.

We work closely with emerging biotech companies to optimize resource allocation and extend their cash runway without compromising strategic objectives. Our support includes developing lean, milestone-driven development plans, prioritizing high-impact activities, and identifying cost-saving opportunities across clinical development, operations, and outsourcing. We also assist in building compelling investor narratives, supporting non-dilutive funding applications, and identifying partnership opportunities to share development risk. Our oncology expertise ensures that every dollar is invested wisely to generate meaningful data and maintain momentum toward key inflection points.